United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

recordati rare diseases uk ltd - haem arginate - solution for infusion - 25mg/1ml

European Union - English - EMA (European Medicines Agency)

recordati netherlands b.v. - siltuximab - giant lymph node hyperplasia - immunosuppressants - sylvant is indicated for the treatment of adult patients with multicentric castleman’s disease (mcd who are human immunodeficiency virus (hiv) negative and human herpesvirus-8 (hhv-8) negative.,

European Union - English - EMA (European Medicines Agency)

recordati netherlands b.v. - dinutuximab beta - neuroblastoma - antineoplastic agents - qarziba is indicated for the treatment of high-risk neuroblastoma in patients aged 12 months and above, who have previously received induction chemotherapy and achieved at least a partial response, followed by myeloablative therapy and stem cell transplantation, as well as patients with history of relapsed or refractory neuroblastoma, with or without residual disease. prior to the treatment of relapsed neuroblastoma, any actively progressing disease should be stabilised by other suitable measures.in patients with a history of relapsed/refractory disease and in patients who have not achieved a complete response after first line therapy, qarziba should be combined with interleukin 2 (il 2).

Israel - English - Ministry of Health

medison pharma ltd - osilodrostat as phosphate - film coated tablets - osilodrostat as phosphate 1 mg - osilodrostat - isturisa is indicated for the treatment of endogenous cushing’s syndrome in adult patients for whom surgery is not an option or has not been curative

Israel - English - Ministry of Health

medison pharma ltd - osilodrostat as phosphate - film coated tablets - osilodrostat as phosphate 10 mg - osilodrostat - isturisa is indicated for the treatment of endogenous cushing’s syndrome in adult patients for whom surgery is not an option or has not been curative

Israel - English - Ministry of Health

medison pharma ltd - osilodrostat as phosphate - film coated tablets - osilodrostat as phosphate 5 mg - osilodrostat - isturisa is indicated for the treatment of endogenous cushing’s syndrome in adult patients for whom surgery is not an option or has not been curative.

Israel - English - Ministry of Health

medison pharma ltd - pasireotide as embonate - powder and solvent for suspension for injection - pasireotide as embonate 20 mg/vial - pasireotide - signifor lar is indicated for the treatment of adult patients with acromegaly for whom surgery is not an option or has not been curative and who are inadequately controlled on treatment with another somatostatin analogue.treatment of adult patients with cushing’s disease for whom surgery is not an option or for whom surgery has failed.

Israel - English - Ministry of Health

medison pharma ltd - pasireotide as embonate - powder and solvent for suspension for injection - pasireotide as embonate 40 mg/vial - pasireotide - signifor lar is indicated for the treatment of adult patients with acromegaly for whom surgery is not an option or has not been curative and who are inadequately controlled on treatment with another somatostatin analogue.treatment of adult patients with cushing’s disease for whom surgery is not an option or for whom surgery has failed.

Israel - English - Ministry of Health

medison pharma ltd - pasireotide as embonate - powder and solvent for suspension for injection - pasireotide as embonate 60 mg/vial - pasireotide - signifor lar is indicated for the treatment of adult patients with acromegaly for whom surgery is not an option or has not been curative and who are inadequately controlled on treatment with another somatostatin analogue.

Israel - English - Ministry of Health

medison pharma ltd - pasireotide as pamoate - powder and solvent for suspension for injection - pasireotide as pamoate 10 mg/vial - pasireotide - treatment of adult patients with cushing’s disease for whom surgery is not an option or for whom surgery has failed.